银屑病患者接受生物制剂治疗的主要心血管事件风险:一项前瞻性队列研究
该前瞻性队列研究基于英国皮肤科医师协会生物制剂与免疫调节剂登记库,比较了乌司奴单抗、TNF-α抑制剂(依那西普和阿达木单抗)以及甲氨蝶呤治疗慢性斑块状银屑病患者的主要心血管事件风险。主要分析纳入5468例生物制剂初治患者,结果显示乌司奴单抗与TNFi之间、乌司奴单抗与阿达木单抗之间、依那西普与阿达木单抗之间以及甲氨蝶呤与阿达木单抗之间的主要心血管事件风险均无显著差异。
要点
- 乌司奴单抗与TNFi的主要心血管事件风险无显著差异(调整HR 0.96,95%CI 0.41-2.22)。
- 乌司奴单抗、依那西普分别与阿达木单抗比较,主要心血管事件风险均无显著差异。
- 甲氨蝶呤与阿达木单抗的主要心血管事件风险无显著差异(调整HR 1.05,95%CI 0.34-3.28)。
核心结论
- 在大型前瞻性队列中,三种生物制剂及甲氨蝶呤治疗银屑病患者的主要心血管事件风险无显著差异。
- 需要更长期随访的研究来探究生物制剂对主要心血管事件发生率的潜在影响。
研究设计与样本
- 前瞻性队列研究,使用英国皮肤科医师协会生物制剂与免疫调节剂登记库数据。
- 主要分析纳入5468例生物制剂初治的慢性斑块状银屑病患者,随后暴露于乌司奴单抗(951例)、依那西普(1313例)或阿达木单抗(3204例)。
- 次要分析额外纳入2189例接受甲氨蝶呤治疗的患者。
- 采用倾向性评分重叠权重计算风险比(HR)及95%置信区间(CI),以平衡组间基线协变量。
主要发现
- 乌司奴单抗、TNFi、阿达木单抗、依那西普和甲氨蝶呤组分别有7、29、23、6和9例患者发生主要心血管事件。
- 乌司奴单抗 vs TNFi的调整HR为0.96(95%CI 0.41-2.22)。
- 乌司奴单抗 vs 阿达木单抗的调整HR为0.81(95%CI 0.30-2.17)。
- 依那西普 vs 阿达木单抗的调整HR为0.81(95%CI 0.28-2.30)。
- 甲氨蝶呤 vs 阿达木单抗的调整HR为1.05(95%CI 0.34-3.28)。
临床怎么用
- 对于慢性斑块状银屑病患者,选择乌司奴单抗、TNFi或甲氨蝶呤时,主要心血管事件风险未见显著差异。
- 临床决策可综合考虑疗效、感染风险等其他因素,而不必因主要心血管事件风险差异而优先选择某一种生物制剂。
局限性
- 随访时间较短(中位随访1.43–2.01年),可能不足以检测长期心血管风险差异。
- 主要心血管事件发生例数较少,置信区间较宽,统计效能有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The cardiovascular safety profile of biologic therapies used for psoriasis is unclear. OBJECTIVES: To compare the risk of major cardiovascular events (CVEs; acute coronary syndrome, unstable angina, myocardial infarction and stroke) in patients with chronic plaque psoriasis treated with adalimumab, etanercept or ustekinumab in a large prospective cohort. METHODS: Prospective cohort study examining the comparative risk of major CVEs was conducted using the British Association of Dermatologists Biologics and Immunomodulators Register. The main analysis compared adults with chronic plaque psoriasis receiving ustekinumab with tumour necrosis-α inhibitors (TNFi: etanercept and adalimumab), whilst the secondary analyses compared ustekinumab, etanercept or methotrexate against adalimumab. Hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated using overlap weights by propensity score to balance baseline covariates among comparison groups. RESULTS: We included 5468 biologic-naïve patients subsequently exposed (951 ustekinumab; 1313 etanercept; and 3204 adalimumab) in the main analysis. The secondary analyses also included 2189 patients receiving methotrexate. The median (p25-p75) follow-up times for patients using ustekinumab, TNFi, adalimumab, etanercept and methotrexate were as follows: 2.01 (1.16-3.21), 1.93 (1.05-3.34), 1.94 (1.09-3.32), 1.92 (0.93-3.45) and 1.43 (0.84-2.53) years, respectively. Ustekinumab, TNFi, adalimumab, etanercept and methotrexate groups had 7, 29, 23, 6 and 9 patients experiencing major CVEs, respectively. No differences in the risk of major CVEs were observed between biologic therapies [adjusted HR for ustekinumab vs. TNFi: 0.96 (95% CI 0.41-2.22); ustekinumab vs. adalimumab: 0.81 (0.30-2.17); etanercept vs. adalimumab: 0.81 (0.28-2.30)] and methotrexate against adalimumab [1.05 (0.34-3.28)]. CONCLUSIONS: In this large prospective cohort study, we found no significant differences in the risk of major CVEs between three different biologic therapies and methotrexate. Additional studies, with longer term follow-up, are needed to investigate the potential effects of biologic therapies on incidence of major CVEs.
引用
- Rungapiromnan W, Mason KJ, Lunt M, et al. Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study. J Eur Acad Dermatol Venereol. 2019. PMID: 31633837. doi:10.1111/jdv.16018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。